FDA approves combination therapy Juvisync

Posted by Food and Drug Administration--Press Releases on Friday Oct 7, 2011 Under News

The U.S. Food and Drug Administration today approved Juvisync (sitagliptin and simvastatin), a fixed-dose combination (FDC) prescription medication that contains two previously approved medicines in one tablet for use in adults who need both sitagliptin and simvastatin.

Be Sociable, Share!

Comments are closed.